Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 19/20 | 0.47 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13451514 | 1.00 | MCL1 (0.47) | MCL1BCL2BCL2L1TACR3 | |
| SCHEMBL13521411 | 1.00 | MCL1 (0.47) | MCL1BCL2BCL2L1TACR3 | |
| SCHEMBL12676433 | 1.00 | MCL1 (0.47) | MCL1BCL2BCL2L1TACR3 | |
| SCHEMBL13521408 | 0.93 | TACR3 (0.41) | MCL1TACR3 | |
| SCHEMBL13997770 | 0.93 | TACR3 (0.41) | MCL1TACR3 | |
| SCHEMBL13521221 | 0.93 | TACR3 (0.41) | MCL1TACR3 | |
| Ammonia Solution, Strong SCHEMBL1901623 | 0.93 | TACR3 (0.40) | MCL1TACR3 | |
| SCHEMBL13997769 | 0.92 | TACR3 (0.40) | MCL1TACR3 | |
| SCHEMBL8274500 | 0.92 | TACR3 (0.40) | MCL1TACR3 | |
| SCHEMBL13521409 | 0.92 | TACR3 (0.40) | MCL1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | MEDIVIR AB (SE) | 2010-01-07 | — | — | US | disclosed |
| US-20080311077-A1 | Antiviral Compounds | GILEAD SCIENCES, INC. | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003216-A1 | HCV NS-3 Serine Protease Inhibitors | SPINT2, SF3A3, GTF3C3 | MCL1 2491/4885BCL2 1815/4885BCL2L1 857/4885 |
| US-20080311077-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | MCL1 1405/4885BCL2 2536/4885BCL2L1 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.